{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:40:08Z","timestamp":1749325208045,"version":"3.41.0"},"reference-count":4,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Calcitonin gene-related peptide antagonists are a novel new class of medications that have been shown to reduce migraine headache pain and bothersome symptoms in patients who have had an insufficient response to triptans or for whom triptans are contraindicated. This article describes the new medications.<\/jats:p>","DOI":"10.1097\/01.jaa.0000835128.83757.c0","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T17:02:23Z","timestamp":1654102943000},"page":"19-20","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Calcitonin gene-related peptide antagonist therapy and migraines"],"prefix":"10.1097","volume":"35","author":[{"given":"Andrew","family":"Zolp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-20250607","first-page":"S3","article-title":"Calcitonin gene-related peptide (CGRP) and migraine","volume":"46","author":"Durham","year":"2006","journal-title":"Headache"},{"journal-title":"Harrison's Principles of Internal Medicine","year":"2018","author":"Jameson","key":"R2-20250607"},{"issue":"10200","key":"R5-20250607","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"R6-20250607","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000835128.83757.c0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:00:30Z","timestamp":1749322830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000835128.83757.c0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000835128.83757.c0","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}